Michael Desch
6PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Mar 28, 2026
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies.HeeJae Choi, Shilpa Madari, Elmar Daalman
|Sep 04, 2025
The Effect of Multiple Oral Doses of a Glycine Transporter 1 Inhibitor, Iclepertin (BI 425809), on the Steady-state Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel: a Phase I Clinical Trial in Healthy Females.Shilpa Madari, Yesilda Balavarca, Yury Shatillo
|Jul 17, 2025
Assessing the Effect of Food on the Pharmacokinetics of Iclepertin in Healthy Volunteers: A Phase I, Open-Label, Randomised, Cross-over Trial.Shilpa Madari, Kerstin Breithaupt-Groegler, Brett A English
|Jun 25, 2025
Evaluation of the Drug-Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach.Elin M Matsson, Michael Desch, Valerie Nock
|Dec 17, 2022
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel
|Oct 30, 2021
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.Michael Desch, Glen Wunderlich, Markus Goettel
Pageof 1
